Skip to main content

Table 3 Multivariate analysis for all clinical outcomes stratified for NCCN risk group and the best-identified cut-point for MIBC (60%)

From: The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for prostate cancer

Covariate

FFBF

FFM

CSS

OS

 

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

NCCN risk group

        

 Low

Reference

 

Reference

 

Reference

 

Reference

 

 Intermediate

1.7 (0.83-3.4)

0.15

2.8 (0.80-9.8)

0.11

2.1 (0.23-19.7)

0.51

1.2 (0.57-2.5)

0.65

 High

3.2 (1.6-6.5)

0.001

4.6 (1.3-16.2)

0.02

6.9 (0.8-59.6)

0.08

3.0 (1.5-6.1)

0.002

MIBC

        

 <60%

Reference

 

Reference

 

Reference

 

Reference

 

 ≥60%

1.9 (1.2-2.9)

0.008

1.6 (0.81-3.1)

0.19

2.2 (0.72-6.9)

0.16

1.0 (0.59-1.7)

0.99

  1. Abbreviations: MIBC = maximum involvement of biopsy core; FFBF = freedom from biochemical failure; FFM = freedom from metastasis; CSS = cause specific survival; OS = overall survival; HR = hazard ratio; CI = confidence interval.